ClinicalTrials.gg
Not yet recruitingNCT06293989VertigoUpdated Apr 2, 2024

Efficacy and Safety of Intravenous Diazepam Given at 2 Different Doses Compared to Placebo in Acute Peripheral Vertigo

A Phase 3 interventional study of Diazepam 5mg and Diazepam 10 mg in Vertigo, Peripheral, sponsored by University of Monastir. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by University of Monastir · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is prospective, randomised double-blind study that will be conducted in the emergency department of 3 university hospitals (FB Monastir, Sahloul Sousse, and FH Sousse) to compare the efficacy of two doses of diazepam (Valium®) and placebo for the relief of acute periphery vertigo in the ED

Read the detailed description

This is prospective, randomised double-blind study that will be conducted in the emergency department of 3 university hospitals (FB Monastir, Sahloul Sousse, and FH Sousse) to compare the efficacy of two doses of diazepam (Valium®) and placebo for the relief of acute periphery vertigo in the ED. The study should be reviewed and receive approval from the institutional review board. Principles of the Helsinki Declaration are considered All patients should provide their informed consent prior to enrollment.

02

Conditions studied

  • Vertigo, Peripheral

Browse trials for

Keywords

  • vertigo
  • diazepam
  • placebo
03

In context

Vertigo

187 studies on the registry are indexed under Vertigo; 27 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 73 across 138 interventional studies indexed under Vertigo.

Browse Vertigo studies →

Lead sponsor

University of Monastir is the lead sponsor of 114 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria;

  • patients between 18 and 70 years of age
  • a chief complaint of acute peripheral vertigo (APV) (sensation of spinning, which was worsened by movement and sudden in onset) were eligible if the treating emergency physician diagnosed an episode of vertigo that was peripheral in nature.

Exclusion Criteria: -Patients aged > 70 years as central vertigo , -patients with a focal neurologic deficit, pregnancy, history of allergic reaction or to any of the test drugs, history of enrolment in a previous clinical drug trial,

  • history of recent ingestion (within 24 hours) of a sedative, antihistamine, antipsychotic, or opioid,
  • history of syncope or cardiac event, considerations of a central origin for vertigo -evidence of drug-induced vertigo or orthostatic hypotension -history of mental or neurological illness.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    diazepam 5 mg

    Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug.

    Drug: Diazepam 5mg

  • Experimental
    diazepam 10 mg

    Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug.

    Drug: Diazepam 10 mg

  • Experimental
    placebo

    Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug.

    Drug: Placebo

Interventions

  • For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam 5 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.

    Also known as: diazepam(B)

  • For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups: diazepam10 mg (5 mg/1 mL), . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.

    Also known as: diazepam(C)

  • DrugPlacebo

    For the intervention, patients will be randomly allocated into three groups. Each patient will be randomized to one of three treatment groups:Placebo . Medications will be diluted with 5 mL of normal saline solution slowly intravenously injected (over 5 minutes). The associate clinical research coordinator was responsible for preparation and dispensing the study drug. The investigators, treating physicians, nurses, and patients were blinded to the treatment.

    Also known as: A

06

What researchers measure

Primary outcomes

  1. Visual analogue scale (VAS)-3H

    the frequency of vertigo resolution defined as a reduction of at least 50% in VAS at 3-hour(VAS-3H) compared to baseline VAS (VAS baseline) during movement (VAS ambulation).

    Time frame: 3 hours

Secondary outcomes

  1. the Delta-VAS

    the delta VAS was calculated as \[(VAS baseline- VAS3H)/VAS baseline\]\*100

    Time frame: 3 hous

  2. the time required to reach the resolution of the vertigo crisis

    the time required to reach the resolution of the vertigo crisis

    Time frame: 3 hours

  3. Patients satisfaction

    patient satisfaction with likert scale

    Time frame: 3 hours

  4. number of patients with adverse effects

    number of patients with adverse effects

    Time frame: 3 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2024; primary completion for Dec 2025, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 5, 2024
StartEst.
May 1, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Mar 30, 2026
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06293989
Responsible party
Pr. Semir Nouira (PROFESSOR, University of Monastir) — Principal investigator
First posted
Mar 5, 2024
Start date
May 1, 2024 (estimated)
Primary completion
Dec 30, 2025 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Apr 2, 2024

Study contacts

NOUIRA Semir, PR
Contact
semir.nouira@rns.tn
73106000 ext. 216
GANNOUN IMEN, ARC
Contact
gannounimen@yahoo.fr
73106000 ext. 216
Nouira semir, Pr
study director · University of Monastir

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion